Northland Securities Forecasts MiMedx Group Q3 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Analysts at Northland Securities cut their Q3 2026 earnings per share (EPS) estimates for shares of MiMedx Group in a research note issued on Friday, April 17th. Northland Securities analyst C. Byrnes now expects that the company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.03. The consensus estimate for MiMedx Group’s current full-year earnings is $0.12 per share. Northland Securities also issued estimates for MiMedx Group’s Q4 2026 earnings at $0.01 EPS.

MDXG has been the subject of a number of other reports. UBS Group set a $10.00 price target on MiMedx Group in a research note on Monday, February 23rd. Cantor Fitzgerald decreased their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. Lake Street Capital decreased their price target on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Wall Street Zen lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Citigroup initiated coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating for the company. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.67.

MiMedx Group Price Performance

NASDAQ:MDXG opened at $3.25 on Monday. MiMedx Group has a 1 year low of $3.20 and a 1 year high of $7.99. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.92. The firm has a market capitalization of $482.85 million, a price-to-earnings ratio of 10.16 and a beta of 1.65. The business has a 50 day simple moving average of $4.42 and a 200-day simple moving average of $5.82.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.

Institutional Investors Weigh In On MiMedx Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Kemnay Advisory Services Inc. bought a new stake in MiMedx Group during the 4th quarter valued at $48,000. State of Alaska Department of Revenue bought a new stake in MiMedx Group during the 3rd quarter valued at $54,000. Headlands Technologies LLC bought a new stake in MiMedx Group during the 2nd quarter valued at $72,000. Jain Global LLC bought a new stake in MiMedx Group during the 4th quarter valued at $73,000. Finally, Virtu Financial LLC bought a new stake in MiMedx Group during the 4th quarter valued at $78,000. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.